362440-2026 cancel Duplicate post published by mistake. There is another valid listing with reference 363094-2026. 16 true false false https://theresa-pcp.eu/ ORG-0001 Fundación Miguel Servet (FMS) Calle Irunlarrea, 3 Pamplona 31008 ES220 ESP ESG31187420 +34 848 42 86 29 unidad.innovacion.salud@navarra.es false false false www.theresa-pcp.eu ORG-0002 Fundación Pública Andaluza Progreso y Salud (FPS) Avda. Américo Vespucio,15, Edificio S-2 Sevilla 41092 ES618 ESP ESG41825811 +34 955 018 000 info@theresa-pcp.eu false false false www.theresa-pcp.eu ORG-0003 Consorci Hospitalari de Vic (CHV) Carrer Francesc Pla “El Vigatà” 1 Vic 08500 ES511 ESP ESQ5856102H +34 938 891 111 info@theresa-pcp.eu false false false www.theresa-pcp.eu ORG-0004 Academisch Ziekenhuis Maastricht (AZM) P. Debyelaan 25 Maastricht 6229HX NL423 NLD NL806096925B01 +31 43 387 6543 info@theresa-pcp.eu false false false www.theresa-pcp.eu ORG-0005 Sihtasutus Põhja-Eesti Regionaalhaigla (PERH) J. Sütiste tee 19 Tallinn 13419 EE001 EST EE100714827 +372 617 1300 info@theresa-pcp.eu false false false www.theresa-pcp.eu ORG-0006 Ziekenhuis Aan De Stroom (ZAS) Kempenstraat 100 Antwerpen 2000 BE211 BEL BE0862382656 +32 32344111 info@theresa-pcp.eu false false false www.theresa-pcp.eu ORG-0007 Wojewódzki Szpital Specjalistyczny W Olsztynie (WSS) UL. Zolnierska 18 Olsztyn 10561 PL622 POL PL7392955794 +48 895 386 356 info@theresa-pcp.eu https://op.europa.eu ORG-0000 Publications Office of the European Union Luxembourg 2417 LU000 LUX PUBL +352 29291 ted@publications.europa.eu 00363988-2026101/20262026-05-28+02:00 2.3 eforms-sdk-1.14 4160f62d-74b7-4334-8b1c-c02f208a85a3 7daebf3d-9e7f-44b2-bcbc-b3c916ad99e5 2026-05-27Z 09:57:03Z 01 32014L0024 cn-standard ENG http://www.theresa-pcp.eu/ body-pl-ra health ORG-0001 ted-esen ORG-0000 http://www.theresa-pcp.eu/ body-pl health ORG-0002 http://www.theresa-pcp.eu/ body-pl health ORG-0003 http://www.theresa-pcp.eu/ body-pl health ORG-0006 http://www.theresa-pcp.eu/ body-pl health ORG-0007 http://www.theresa-pcp.eu/ body-pl health ORG-0005 http://www.theresa-pcp.eu/ body-pl health ORG-0004 epo-procurement-document PRE-COMMERCIAL PROCUREMENT THERESA PCP seeks to develop innovative and sustainable technologies for on-site treatment of hospital wastewater that demonstrate high-performance while resulting in environmental added value. This PCP – i.e. a joint cross-border procurement of R&D services – is intended to reinforce public demand-driven innovation. PCP has the potential to be an effective demand-side innovation action and a useful tool to close the gap between supply and demand for innovative solutions. Solutions are expected to achieve TRL 7-9 at the end of Phase 31.The PCP should deliver successful innovative and fully tested product(s) and/or service(s) that meet the common challenge of the PBG to procure R&D and innovative marketable solutions, speed up the time-to-market and provide best value for money. The R&D for THERESA PCP will be split into 3 phases (Phase 1: solution design, Phase 2: prototyping and lab testing, Phase 3: original development, installation, wider field testing and validation of a limited set of ‘first’ products or services). PCP PHASE 1 – SOLUTION DESIGN: During this phase, the contractors will be asked to present the concept and describe the solution providing the complete architecture and design thereof and present relevant supporting documentation enabling verification of the technical, economic and organisational feasibility of their solution to address the PCP challenge. PCP PHASE 2 – PROTOTYPE DEVELOPMENT: This phase concerns the development of prototypes of the solutions and testing their performance under controlled conditions. Based on the conceptual designs and documentation presented in phase 1, the contractors shall develop a prototype of the solution and perform its testing under laboratory conditions to demonstrate its performance in terms of measurable technical parameters related to the performance of the technology in fulfilling its purpose related to THERESA PCP challenge and environmental parameters related to the environmental aspects or impacts during its operation. During and at the end of phase 2, the PBG will request from the contractors a series of deliverables in order to evaluate their progress, the performed activities and the obtained results, as well as an end of phase report. PCP PHASE 3 – VALIDATION IN REAL OPERATIONAL ENVIRONMENT: This phase will validate the final solutions through independent verification and third-party test data generation to demonstrate their technical/functional and environmental performance achieved under real hospital conditions, using . detailed scenarios and processes developed in the verification and validation strategy. Evaluations by the relevant committee after each phase will progressively identify the solutions that offer the best value for money and meet the customers’ needs. This phased approach allows successful contractors to improve their offers for the next phase, based on lessons learnt and feedback from procurers in the previous phase. Tender closing time will be: 31 August 2026, 23:59 CEST (local time in Spain) Following the tendering stage, a Framework Agreement and a Specific Contract for phase 1 will be awarded to at least 5 (five) contractors. If less contractors than 5 (five) will present a bid, the PBG shall motivate a decision to stop or continue the PCP2. A call-off will be organized for phase 2, with the aim of awarding 3 phase 2 contracts. Only offers from contractors that successfully completed phase 1 will be eligible for phase 2. The procurers will validate the phase 2 prototypes. A second call-off will be organized for phase 3, with the aim of awarding a minimum of 2 phase 3 contracts. Only offers from contractors that successfully completed phase 2 will be eligible for phase 3. Testing of the first products/services is expected to take place in the test sites indicated in Tender Documents - Annex 1. Testing sites during phase 3. open 720765-2025 false THERESA PCP PreCommercial Procurement of innovative and sustainable solutions to Treat HEalthcaRE System wAstewater. services PCP procurements are exempted from the EU Public Procurement Directives because the procurers do not retain all the benefits of the R&D (the IPR ownership stays with the contractors). They are also exempted from the WTO GPA because this Agreement does not cover R&D services (the PCP being limited to such services and any subsequent PPI relating to commercialscale supply of such solutions not being part of the PCP). The Tender Documents and other specifications will be available for download on the website: https://theresa-pcp.eu. In addition, proposals must be submitted through the Tuttogare procurement platform. The link to this platform is as follows: https://theresapcp.tuttogare.it/ Interested bidders who wish to submit their proposals must first register as users on the platform. Furthermore, the THERESA-PCP website will provide a guide on how to use the Tuttogare platform, including instructions for downloading documents and submitting proposals. For any inquiries, questions may be submitted through the Tuttogare platform. They will also find additional information regarding the procedure and the documents to be submitted in each phase, organized according to their intended use in the THERESA - PCP website. For any further inquiries, you are kindly requested to direct your correspondence to the following email addresses: Email: info@theresa-pcp.eu Email: unidad.innovacion.salud@navarra.es THERESA PCP Coordination Team 2824143.04 73100000 38434000 38430000 38434500 38434560 42910000 42912100 42912300 42961000 42912310 42996000 71620000 71900000 72222300 72227000 73111000 90730000 Pamplona ES220 ESP ES618 ESP ES511 ESP NL423 NLD EE001 EST PL622 POL LOT-0001 HORIZONEU eu-funds ENG THERESA - PCP Tender documents non-restricted-document https://theresa-pcp.eu/ epo-procurement-document none no allowed false not-allowed quality A.1.Removal Rates quality A.2.Contaminants quality A.3.Operational and Technical Criteria quality A.4.Sustainability aspects quality B.1.Quality of the methodology – Design, development and installation of the solution quality B.2.Technical validity and robustness of the solution proposed quality C.1.Commercial potential quality C.2.Implementation methodology price Financial offer https://theresapcp.tuttogare.it/ 60 Considering that PCP is exempted from the EU Public Procurement Directives and subsequently from the national transposition laws, the Spanish (and Navarra´s) public procurement law will be applied on a subsidiary basis, if the tender documents do not cover a potential legal loophole. Any legal claim, petition or application for judicial review, with regard to the execution of this Phase 1 Contract, shall be lodged: • For contract modifications: before the Head of the Department of Health of Navarre (Spain), within a period of one month from the publication or notification of the contested decision. This prior appeal is mandatory before escalating to the administrative courts of Pamplona (Navarra, Spain) for a period of two month after the decision of the Head of the Department of Health of Navarre • For the execution and termination of the contract(s): before the civil courts of Pamplona (Navarra, Spain). ORG-0001 ENG false true Tuttogare required false https://theresapcp.tuttogare.it/ 2026-08-31+02:00 23:59:00+02:00 2026-07-27+02:00 23:59:00+02:00 https://theresapcp.tuttogare.it/ false none none THERESA - PCP THERESA PCP seeks to develop innovative and sustainable technologies for on-site treatment of hospital wastewater that demonstrate high-performance while resulting in environmental added value. This PCP – i.e. a joint cross-border procurement of R&D services – is intended to reinforce public demand-driven innovation. PCP has the potential to be an effective demand-side innovation action and a useful tool to close the gap between supply and demand for innovative solutions. Solutions are expected to achieve TRL 7-9 at the end of Phase 31.The PCP should deliver successful innovative and fully tested product(s) and/or service(s) that meet the common challenge of the PBG to procure R&D and innovative marketable solutions, speed up the time-to-market and provide best value for money. The R&D for THERESA PCP will be split into 3 phases (Phase 1: solution design, Phase 2: prototyping and lab testing, Phase 3: original development, installation, wider field testing and validation of a limited set of ‘first’ products or services). PCP PHASE 1 – SOLUTION DESIGN: During this phase, the contractors will be asked to present the concept and describe the solution providing the complete architecture and design thereof and present relevant supporting documentation enabling verification of the technical, economic and organisational feasibility of their solution to address the PCP challenge. PCP PHASE 2 – PROTOTYPE DEVELOPMENT: This phase concerns the development of prototypes of the solutions and testing their performance under controlled conditions. Based on the conceptual designs and documentation presented in phase 1, the contractors shall develop a prototype of the solution and perform its testing under laboratory conditions to demonstrate its performance in terms of measurable technical parameters related to the performance of the technology in fulfilling its purpose related to THERESA PCP challenge and environmental parameters related to the environmental aspects or impacts during its operation. During and at the end of phase 2, the PBG will request from the contractors a series of deliverables in order to evaluate their progress, the performed activities and the obtained results, as well as an end of phase report. PCP PHASE 3 – VALIDATION IN REAL OPERATIONAL ENVIRONMENT: This phase will validate the final solutions through independent verification and third-party test data generation to demonstrate their technical/functional and environmental performance achieved under real hospital conditions, using . detailed scenarios and processes developed in the verification and validation strategy. Evaluations by the relevant committee after each phase will progressively identify the solutions that offer the best value for money and meet the customers’ needs. This phased approach allows successful contractors to improve their offers for the next phase, based on lessons learnt and feedback from procurers in the previous phase. Tender closing time will be: 31 August 2026, 23:59 CEST (local time in Spain) Following the tendering stage, a Framework Agreement and a Specific Contract for phase 1 will be awarded to at least 5 (five) contractors. If less contractors than 5 (five) will present a bid, the PBG shall motivate a decision to stop or continue the PCP2. A call-off will be organized for phase 2, with the aim of awarding 3 phase 2 contracts. Only offers from contractors that successfully completed phase 1 will be eligible for phase 2. The procurers will validate the phase 2 prototypes. A second call-off will be organized for phase 3, with the aim of awarding a minimum of 2 phase 3 contracts. Only offers from contractors that successfully completed phase 2 will be eligible for phase 3. Testing of the first products/services is expected to take place in the test sites indicated in Tender Documents - Annex 1. Testing sites during phase 3. services true proc-innov 2824143.04 73100000 Anywhere in the European Economic Area ES220 ESP ES618 ESP ES511 ESP NL423 NLD BE211 BEL EE001 EST PL622 POL 2027-01-04+01:00 2029-07-27+02:00